KLRA

Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Wednesday, September 23, 2026, 9:40 a.m.

Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a $2.40 billion market cap.

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the second quarter ended June 30, 2026, and provided a summary of recent business highlights.

Kailera is building a multi-modal obesity franchise with exclusive global rights to Hengrui Pharma's obesity portfolio, leveraging late-stage assets and ongoing data. KLRA's robust cash position—over $1.3 billion post-IPO—funds operations through mid-2028, supporting multiple pivotal trial readouts before further capital is needed. Pipeline catalysts include global Phase 3 trials for ribupatide and promising Phase 2/3 data for oral GLP-1 candidates, targeting differentiated efficacy and convenience.

Kailera ​Therapeutics said ‌on ​Tuesday ​its GLP-1 ⁠drug ​for patients ​with diabetes ​and ​obesity met the ‌main ⁠goal of ​two-late ​stage ⁠trials.

Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.

WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, including new topline data from Phase 3 trial of oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes, and first-in-human topline data from Phase 1 trial for injectable tri-agonist HRS-4729 (KAI-4729) Cash on hand, including IPO proceeds, is expected to fund operations into mid-2028 WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the first quarter ended March 31, 2026, and provided a summary of recent business highlights.